Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy

Inclusion Criteria:

* Histologically confirmed Hodgkin's lymphoma at time of relapse or disease progression, meeting all of the following criteria:

  * Stage I-IV disease
  * No morphologically unclassifiable disease
* Meets 1 of the following criteria:

  * Mixed cellularity
  * Lymphocytic depletion (LD)
  * LD, diffuse fibrosis
  * LD, reticular
  * Lymphocyte predominance (LP)
  * LP, diffuse
  * LP, nodular
  * Nodular sclerosis (NS)
  * NS, cellular phase
  * NS, lymphocytic predominance
  * NS, mixed cellularity
  * NS, LD
  * Not otherwise specified
* Primary refractory disease OR disease in first relapse, except for the following:

  * Patients who achieved a complete response after treatment on protocol COG-AHOD0431 who experience a biopsy-proven recurrence after doxorubicin hydrochloride, vincristine, prednisone, and cyclophosphamide without involved-field radiotherapy
  * Patients on the observation-only arm of protocol COG-AHOD0431
* Any measurable, focal mass lesion of a visceral organ (e.g., liver, spleen, or kidney)
* Patients with metastatic disease to bone marrow and granulocytopenia, anemia, and/or thrombocytopenia are allowed provided both of the following criteria are met:

  * Platelet count ≥ 20,000/mm³ (platelet transfusion allowed)
  * Hemoglobin ≥ 8 g/dL (packed red blood cell transfusion allowed)
* Karnofsky performance status (PS) 60-100% (for patients \> 16 years of age) OR Lanksy PS 60-100% (for patients =\< 16 years of age)
* Life expectancy \>= 2 months
* Absolute neutrophil count \>= 1,000/mm\^3
* Platelet count \>= 75,000/mm\^3 (transfusion independent) (for patients with no bone marrow involvement)
* Creatinine =\< 1.5 times upper limit of normal (ULN)
* Creatinine clearance or radioisotope glomerular filtration rate \>= 70 mL/min/1.73 m\^2
* AST and ALT =\< 2.5 times ULN
* Bilirubin =\< 1.5 times ULN
* Shortening fraction \>= 27% by echocardiogram OR LVEF \>= 50% by gated radionuclide study
* Patients with a seizure disorder are eligible if on a nonenzyme-inducing anticonvulsant and seizures are well controlled
* No CNS toxicity \> grade 2
* No serious intercurrent illnesses
* No known hypersensitivity to E. coli-derived proteins, filgrastim (G-CSF), or any component of the study drugs
* No peripheral neuropathy \> grade 1
* No known hypersensitivity to bortezomib, boron, or mannitol
* No other concurrent chemotherapy or immunomodulating agents (including steroids)

  * Concurrent corticosteroids allowed for treatment or prophylaxis of anaphylactic reactions
  * No dexamethasone or aprepitant as an antiemetic
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* Recovered from prior therapy
* No prior bortezomib or other proteasome inhibitors
* At least 3 weeks since prior chemotherapy (4 weeks for nitrosoureas)
* More than 14 days since prior investigational drugs
* No concurrent enzyme inducing anticonvulsants that alter p450 metabolism, including phenytoin, carbamazepine, phenobarbital, or other anticonvulsants

  * Benzodiazepine or gabapentin allowed